SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (3624)1/15/1998 9:58:00 PM
From: JOHN W.  Respond to of 6136
 
KEY EVENTS TO DRIVE PRICE APPRECIATION

PW (1/13/98) Elise Wang:

--"We expect European and Canadian approval (as well as Brazil, Japan and New Zealand) during this calendar quarter. Agouron's marketing partner, Roche, has scheduled a European market launch meeting in early March in anticipation of approval, AND HAS RECEIVED PRELIMINARY APPROVAL FROM THE EUROPEAN REGULATORY AUTHORITIES."

--"Initiation of a Phase II/III clinical study of AG3340, MMP Inhibitor, for solid tumors later this quarter. The product is currently in a Phase I/II study. PRELIMINARY RESULTS HAVE BEEN PROMISING."



To: JOHN W. who wrote (3624)1/15/1998 10:03:00 PM
From: JOHN W.  Respond to of 6136
 
Since it hit 36 today, I would expect a close for the week close to that number.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News